Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN1002725 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Leucine-Rich Repeat LGI Family, Member 2 (LGI2) (N-Term) antibody
- Antibody type
- Polyclonal
- Antigen
- LGI2 antibody was raised in rabbits against an 11 amino acid peptide from near the amino terminus of human LGI2.
- Description
- Affinity chromatography purified via peptide column.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Epitope
- N-Term
- Isotype
- IgG
- Vial size
- 100 μg
- Storage
- 4°C
- Handling
- Antibody can be stored at 4ºC, stable for one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. During shipment, small volumes of antibody will occasionally become entrapped in the seal of the product vial. For products with volumes of 200 myl or less, we recommend gently tapping the vial on a hard surface or briefly centrifuging the vial in a tabletop centrifuge to dislodge any liquid in the container?s cap.
Submitted references Using gene-history and expression analyses to assess the involvement of LGI genes in human disorders.
LGI1 mutations in temporal lobe epilepsies.
A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors.
Gu W, Gibert Y, Wirth T, Elischer A, Bloch W, Meyer A, Steinlein OK, Begemann G
Molecular biology and evolution 2005 Nov;22(11):2209-16
Molecular biology and evolution 2005 Nov;22(11):2209-16
LGI1 mutations in temporal lobe epilepsies.
Berkovic SF, Izzillo P, McMahon JM, Harkin LA, McIntosh AM, Phillips HA, Briellmann RS, Wallace RH, Mazarib A, Neufeld MY, Korczyn AD, Scheffer IE, Mulley JC
Neurology 2004 Apr 13;62(7):1115-9
Neurology 2004 Apr 13;62(7):1115-9
A novel gene, LGI1, from 10q24 is rearranged and downregulated in malignant brain tumors.
Chernova OB, Somerville RP, Cowell JK
Oncogene 1998 Dec 3;17(22):2873-81
Oncogene 1998 Dec 3;17(22):2873-81
No comments: Submit comment
No validations: Submit validation data